Biosimilars are rapidly transforming the U.S. pharmaceutical market amid rising healthcare costs and a shift in interchangeability policy. Market competition is intensifying, with some biosimilars offering wholesale and ASP discounts, signaling significant cost savings and ultimately broader adoption.

FDA drug approval delays due to government cuts are happening but not widespread yet. Early signs and staffing challenges suggest the situation could worsen over time.

Jeffrey Casberg, M.S., Vice President of Clinical Pharmacy at IPD Analytics, shared his input on Managed Healthcare Executive’s annual Pharmacy Survey results.

espite the transformative potential of cell and gene therapies, widespread adoption remains limited due to systemic gaps in infrastructure, reimbursement models, and coordination of care.

In this report, you’ll learn from experts commenting on key challenges and emerging solutions within this space, including how cell gene therapies are revolutionizing patient care while creating new challenges for us as an industry.